The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

Vaxcyte's stock surges on promising vaccine data, offering potential upside despite competition. Learn more on PCVX here.

STAT's podcast The Readout LOUD this week discusses cannabinoid receptor drugs in weight loss, what the Fed's rates cut might ...

Hi there, this is Ailbhe Rea, a Bloomberg UK Associate editor based in Westminster. Rachel Reeves, if you’re reading, look ...

Israel and Hezbollah exchanged cross-border strikes as Lebanon reels from deadly back-to-back attacks targeting the electronic devices of the Iran-backed militant group’s members that left dozens dead ...

Despite the analysts’ downbeat assessment, Oliver Sartor, M.D., Director of Radiopharmaceutical Trials and Professor of ...

Viking Therapeutics (VKTX) stock rises as J.P. Morgan gives a buy-equivalent rating on upcoming Phase 1 trial results for ...

Wilde, a Bloomberg UK journalist and editor on the Readout. Hope you enjoy today’s newsletter. Well, what a pivot week this ...

Shares in Insmed have rocketed after the biotech reported positive results in a highly-anticipated clinical trial of brensocatib in the respiratory disorder bronchiectasis. The phase 3 trial ...

The positive readout in patients with non-relapsing secondary progressive multiple sclerosis comes on the heels of ...

JPMorgan analyst Hardik Parikh initiated coverage on Viking Therapeutics with an Overweight rating and a December 2025 price target of $80.

Keysight Technologies, Inc. (NYSE: KEYS) introduces Quantum Circuit Simulation (Quantum Ckt Sim), an innovative circuit design environment that speeds ...